Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
795
-
Total 13F shares, excl. options
-
129M
-
Shares change
-
-2.45M
-
Total reported value, excl. options
-
$59B
-
Value change
-
-$778M
-
Put/Call ratio
-
1.16
-
Number of buys
-
483
-
Number of sells
-
-263
-
Price
-
$456.00
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q3 2025
894 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q3 2025.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 795 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 129M shares
of 132M outstanding shares and own 98.38% of the company stock.
Largest 10 shareholders include FMR LLC (16.8M shares), Capital World Investors (16.4M shares), VANGUARD GROUP INC (13.6M shares), BlackRock, Inc. (9.9M shares), Capital Research Global Investors (7.22M shares), JPMORGAN CHASE & CO (4.54M shares), STATE STREET CORP (3.08M shares), BAILLIE GIFFORD & CO (2.79M shares), GEODE CAPITAL MANAGEMENT, LLC (2.5M shares), and Dodge & Cox (2.32M shares).
This table shows the top 795 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.